nach oben

Erschienen in:

01.03.2003 | Original Article

Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2

verfasst von: T. J. P. Spoormakers, W. R. Klein, J. J. L. Jacobs, Th. S. G. A. M. Van Den Ingh, J. W. Koten, W. Den Otter

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Local interleukin-2 (IL-2) is effective in a number of experimental animal models and in veterinary and human cancer patients without discomforting side effects. The primary goal of this study was to compare the therapeutic effects and side effects of the local intratumoral administration of five or ten low doses of IL-2 with those of a combination of cisplatin and a single high dose of IL-2 in the treatment of equine sarcoids. The therapeutic effect (complete and partial regression) of local cisplatin together with a single high dose of IL-2 was significantly better than the combined effect of low doses of local IL-2 administered daily over 5 or 10 days (80% and 43%, respectively; P=0.02). Cisplatin/IL-2 and low doses of IL-2 induced 53% and 14% complete regressions, respectively (P=0.02). Histological changes after cisplatin/IL-2 treatment were far more pronounced than after IL-2 only treatment and in several cases showed an enormous eosinophilic infiltrate.

Bernsen MR (1993) Local chemo-immunotherapy with low doses of cisplatin and recombinant interleukin-2 in three murine tumor models. Thesis, Utrecht University

Bernsen MR, Dullens HFJ, Den Otter W, Heintz APM (1992) Chemo-immunotherapy with a combination of low-dose cisplatin and recombinant interleukin 2. In: Sharp F, Mason WP, Creasman W (eds) Ovarian cancer 2. Biology, diagnosis and management. Chapman and Hall, London, p 189

Bernsen MR, Van Der Velden AW, Everse LA, Dullens HFJ, Den Otter W, Heintz APM (1998) Interleukin-2: hope in cases of cisplatin-resistant tumours. Cancer Immunol Immunother 46:41CrossRefPubMed

Bubenik J, Indrova M (1987) Cancer immunotherapy using local interleukin-2 administration. Immunol Lett 16:305CrossRefPubMed

Characiejus D, Dullens HF, Den Otter W (1990) Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system. Cancer Immunol Immunother 32:179PubMed

Costain DJ, Guha AK, Liwski RS, Lee TDG (2001) Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism. Cancer Immunol Immunother 50:293PubMed

De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W (1991) Tumor regression by IL-2 mediated stagnation of blood flow. In Vivo 5:679PubMed

Den Otter W, Maas RA, Koten JW, Dullens HFJ, Bernsen M, Klein WR, Rutten VPMG, Steerenberg PA, Balemans L, Ruitenberg EJ, Hill FWG, Heintz APM (1991) Effective immunotherapy with local low doses of interleukin-2. In Vivo 5:561PubMed

Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rutten VPMG, Ruitenberg EJ (1993) Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13:2453PubMed

10.

Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode Ch, Stewart R, Faber JAJ, Ruitenberg EJ, Rutten VPMG (1995) Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10PubMed

11.

Den Otter W, Dobrowolski Z, Bugajski A, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159:1183PubMed

12.

Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennnink WE, Stewart R (1999) Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. Cancer Immunol Immunother 48:419CrossRefPubMed

13.

Den Otter W, Balemans L, Battermann JJ, Bernsen MR, Cadée JA, Dobrowolski Z, Fiszer-Maliszewska L, Gavhumende R, De Groot JW, Hennink WE, Hill FWG, Jurgenliemp-Schultz I, Klein WR, Koten JW, Maas RA, Steerenberg P, Stewart R, Zembala M (1999) Local low-dose IL-2 therapy. Hepatogastroenterology 46:1280PubMed

14.

Everse LA, Bernsen MR, Dullens HJF, Den Otter W (1996) The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration. J Exp Ther Oncol 1:231PubMed

15.

Everse LA, Bernsen MR, Dullens HJF, Den Otter W (1997) Anti-tumor response promotes efficiency of interleukin-2 therapy. Cancer Immunol Immunother 44:221CrossRefPubMed

16.

Forni G, Giovarelli M (1987) Tumor immunotherapy with interleukin-2 and leucocytes. Res Monogr Immunol 11:263

17.

Goodrich L, Gerber H, Marti E, Antczak DF (1998) Equine sarcoids. Vet Clin North Am Equine Pract 14:607PubMed

18.

Hill FWG, Klein WR, Hoyer MJ, Rutten VPMG, Kock N, Koten JW, Steerenberg PA, Ruitenberg EJ, Den Otter W (1994) Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 41:19CrossRefPubMed

19.

Iwasaki K, Torisu M, Fujimura T (1986) Malignant tumor and eosinophils: prognostic significance in gastric cancer. Cancer 58:1321PubMed

20.

Jackson C (1936) The incidence and pathology of tumours of domestic animals in South Africa. Onderstepoort J Vet Sci Animal Industry 6:378

21.

Kinnunen RE, Tallberg Th, Stenbäck H, Sarna S (1999) Equine sarcoid tumour treated by autogenous tumour vaccine. Anticancer Res 19:3367PubMed

22.

Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ (1986) Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother 21:133PubMed

23.

Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 49:7037PubMed

24.

Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 33:389PubMed

25.

Martens A, De Moor A, Vlaminck L, Pille F, Steenhaut M (2001) Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids. Vet Rec 149:665PubMed

26.

Mattijssen V, Balemans LTM, Steerenberg PA, De Mulder PHM (1992) Polyethylene glycol-modified interleukin-2 is superior to interleukin-2 in local-regional immunotherapy of established guinea pig tumors. Int J Cancer 51:812PubMed

27.

Olson C (1948) Equine sarcoid, a cutaneous neoplasm. Am J Vet Res 9:333

28.

Peace DJ, Cheever MA (1989) Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169:161PubMed

29.

Pizza C, Severini G, Menniti D, de Vinci C, Corrado F (1984) Tumor regression after intralesional injection of interleukin-2 in bladder cancer. Int J Cancer 34:359

30.

Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG II, Kimball PM, Boohaker EA (1983) Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43:2997PubMed

31.

Rivoltini L, Viggiano V, Spinazzè S, Santoro A, Colombo MP, Takatsu K, Parmiani G (1993) In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 54:8PubMed

32.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetti JT, Seipp RN, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313:1485PubMed

33.

Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169PubMed

34.

Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Lineham WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474PubMed

35.

Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, Den Otter W, Steerenberg PA, De Jong WH, Ruitenberg EJ (1989) Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. Cancer Immunol Immunother 30:165PubMed

36.

Silberstein DS, Schoof DD, Rodrick ML, Tai PC, Spry CJF, David JR, Eberlein TJ (1989) Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol 142:2162PubMed

37.

Studer U, Marti E, Stornetta D, Lazary S, Gerber H (1997) The therapy of equine sarcoid with a non-specific immunostimulator—the epidemiology and spontaneous regression of sarcoids (in German). Schweiz Arch Tierheilkd 139:385PubMed

38.

Sundberg JP, Burnstein T, Page EH, Kirkha WW, Robinson FR (1977) Neoplasms of equidae. J Am Vet Med Assoc 2:150

39.

Théon AP, Pascoe JR, Carlson GP, Krag DN (1993) Intratumoral chemotherapy with cisplatin in oily emulsion in horses. J Am Vet Med Assoc 202:261PubMed

40.

Vaage J (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 47:4296PubMed

41.

Van Haelst-Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, Dennin R, Abrams JS (1991) Administration of interleukin-2 (IL-2) results in increased plasma concentration of IL-5 and eosinophilia in patients with cancer. Blood 78:1538PubMed

42.

Vanselow BA, Abetz I, Jackson AR (1988) BCG emulsion immunotherapy of equine sarcoid. Equine Vet J 20:444PubMed

43.

Ziekman PGPM (1999) Local low-dose IL-2 therapy of tumours in companion animals. Anticancer Res 19:2016

Titel: Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2
verfasst von: T. J. P. Spoormakers
W. R. Klein
J. J. L. Jacobs
Th. S. G. A. M. Van Den Ingh
J. W. Koten
W. Den Otter
Publikationsdatum: 01.03.2003
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2003
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-002-0369-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody

Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells

IL-12: a promising adjuvant for cancer vaccination

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie